Trial Profile
A Phase I and Pharmocologic Study of MM-121 in Patients With Refractory Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Seribantumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Fallopian tube cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Thymic epithelial tumour; Urethral cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 11 Jul 2021 Results published in the Investigational New Drugs
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2012 Planned end date changed from 1 Jul 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.